We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cytomedix, | AMEX:GTF | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Delaware
|
01-32518
|
23-3011702
|
(State
or Other Jurisdiction
|
(Commission
|
(I.R.S.
Employer
|
of
Incorporation)
|
File
Number)
|
Identification
No.)
|
(a)
|
The
Company adopted the FASB Emerging Issues Task Force’s Issue No 07-5,
“Determining Whether an
Instrument (or Embedded Feature) is Indexed to an Entity’s own
Stock”
(“EITF 07-5”), now codified in ASC 815-40, as of January 1,
2009. EITF 07-5 provides guidance as to assessing equity versus
liability treatment and classification for equity-linked financial
instruments, including stock purchase warrants. Upon the
adoption of EITF 07-5, the Company did not properly assess the impact of
certain non-standard anti-dilution provisions that existed in certain
then-outstanding stock purchase warrants, resulting in equity (versus
liability) treatment and
classification.
|
(b)
|
In
2009, the Company did not properly assess the impact of certain
non-standard anti-dilution provisions that existed in stock purchase
warrants issued in the August 2009 offering, resulting in equity (versus
liability) treatment and
classification.
|
(c)
|
As
a result of the improper accounting treatment of the above-mentioned
warrants, certain offering expenses were also misclassified and accounted
for incorrectly.
|
2009
Quarter to Date
|
||||||||||||||||
March
31
|
June
30
|
September
30
|
December
31
|
|||||||||||||
Net
Loss to Common Shareholders
|
||||||||||||||||
As
reported
|
$
|
(894,630
|
)
|
$
|
(890,666
|
)
|
$
|
(570,425
|
)
|
$
|
(1,097,814
|
)
|
||||
Error
|
$
|
(52,241
|
)
|
$
|
(276,751
|
)
|
$
|
(105,144
|
)
|
$
|
613,503
|
|||||
As
restated
|
$
|
(946,871
|
)
|
$
|
(1,167,417
|
)
|
$
|
(675,569
|
)
|
$
|
(484,311
|
)
|
||||
|
||||||||||||||||
Net
Loss per Common Share
|
||||||||||||||||
As
reported
|
$
|
(0.03
|
)
|
$
|
(0.03
|
)
|
$
|
(0.02
|
)
|
$
|
(0.03
|
)
|
||||
Error
|
$
|
-
|
$
|
(0.01
|
) |
$
|
-
|
$
|
0.02
|
|||||||
As
restated
|
$
|
(0.03
|
)
|
$
|
(0.03
|
)
|
$
|
(0.02
|
)
|
$
|
(0.01
|
)
|
||||
2009
Year to Date
|
||||||||||||||||
March
31
|
June
30
|
September
30
|
December
31
|
|||||||||||||
Net
Loss to Common Shareholders
|
||||||||||||||||
As
reported
|
$
|
(894,630
|
)
|
$
|
(1,785,296
|
)
|
$
|
(2,355,721
|
)
|
$
|
(3,453,535
|
)
|
||||
Error
|
$
|
(52,241
|
)
|
$
|
(328,992
|
)
|
$
|
(434,136
|
)
|
$
|
179,367
|
|||||
As
restated
|
$
|
(946,871
|
)
|
$
|
(2,114,288
|
)
|
$
|
(2,789,857
|
)
|
$
|
(3,274,168
|
)
|
||||
|
||||||||||||||||
Net
Loss per Common Share
|
||||||||||||||||
As
reported
|
$
|
(0.03
|
)
|
$
|
(0.05
|
)
|
$
|
(0.07
|
)
|
$
|
(0.10
|
)
|
||||
Error
|
$
|
-
|
$
|
(0.01
|
)
|
$
|
(0.01
|
)
|
$
|
0.01
|
||||||
As
restated
|
$
|
(0.03
|
)
|
$
|
(0.06
|
)
|
$
|
(0.08
|
)
|
$
|
(0.09
|
)
|
||||
|
||||||||||||||||
As
of
|
||||||||||||||||
March
31, 2009
|
June
30, 2009
|
September
30, 2009
|
December
31, 2009
|
|||||||||||||
Derivative Liabilities | ||||||||||||||||
As
reported
|
$ | - | $ | - | $ | - | $ | - | ||||||||
Error
|
$ | 178,393 | $ | 453,176 | $ | 1,242,058 | $ | 623,853 | ||||||||
As
restated
|
$ | 178,393 | $ | 453,176 | $ | 1,242,058 | $ | 623,853 | ||||||||
|
As
of
|
|||||||||||||||
|
March
31, 2009
|
June
30, 2009
|
September
30, 2009
|
December
31, 2009
|
||||||||||||
Stockholders'
Equity
|
||||||||||||||||
As
reported
|
$
|
2,336,706
|
$
|
1,571,804
|
$
|
2,556,900
|
$
|
1,546,906
|
||||||||
Error
|
$
|
(170,517
|
)
|
$
|
(447,269
|
)
|
$
|
(1,184,358
|
)
|
$
|
(570,855
|
)
|
||||
As
restated
|
$
|
2,166,189
|
$
|
1,124,535
|
$
|
1,372,542
|
$
|
976,051
|
||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Quarter
to Date
|
|||||||||||||||
|
March
31, 2010
|
June
30, 2010
|
September
30, 2010
|
|||||||||||||
Net
Loss to Common Shareholders
|
||||||||||||||||
As
reported
|
$
|
(1,064,623
|
)
|
$
|
(3,869,775
|
)
|
$
|
(1,690,186
|
)
|
|||||||
Error
|
$
|
(6,759
|
)
|
$
|
(422,472
|
)
|
$
|
180,485
|
||||||||
As
restated
|
$
|
(1,071,382
|
)
|
$
|
(4,292,247
|
)
|
$
|
(1,509,701
|
)
|
|||||||
|
||||||||||||||||
Net
Loss per Common Share
|
||||||||||||||||
As
reported
|
$
|
(0.03
|
)
|
$
|
(0.10
|
)
|
$
|
(0.04
|
)
|
|||||||
Error
|
$
|
-
|
$
|
(0.01
|
)
|
$
|
-
|
|||||||||
As
restated
|
$
|
(0.03
|
)
|
$
|
(0.11
|
)
|
$
|
(0.04
|
)
|
|||||||
|
||||||||||||||||
|
Year
to Date
|
|||||||||||||||
|
March
31, 2010
|
June
30, 2010
|
September
30, 2010
|
|||||||||||||
Net
Loss to Common Shareholders
|
||||||||||||||||
As
reported
|
$
|
(1,064,623
|
)
|
$
|
(4,934,398
|
)
|
$
|
(6,624,584
|
)
|
|||||||
Error
|
$
|
(6,759
|
)
|
$
|
(429,231
|
)
|
$
|
(248,746
|
)
|
|||||||
As
restated
|
$
|
(1,071,382
|
)
|
$
|
(5,363,629
|
)
|
$
|
(6,873,330
|
)
|
|||||||
|
||||||||||||||||
Net
Loss per Common Share
|
||||||||||||||||
As
reported
|
$
|
(0.03
|
)
|
$
|
(0.13
|
)
|
$
|
(0.18
|
)
|
|||||||
Error
|
$
|
-
|
$
|
(0.01
|
)
|
$
|
-
|
|||||||||
As
restated
|
$
|
(0.03
|
)
|
$
|
(0.14
|
)
|
$
|
(0.18
|
)
|
As
of
|
||||||||||||||||
March
31, 2010
|
June
30, 2010
|
September
30, 2010
|
||||||||||||||
Derivative
Liabilities
|
||||||||||||||||
As
reported
|
$ | - | $ | - | $ | - | ||||||||||
Error
|
$ | 625,909 | $ | 880,075 | $ | 696,856 | ||||||||||
As
restated
|
$ | 625,909 | $ | 880,075 | $ | 696,856 |
As
of
|
||||||||||||||||
March
31, 2010
|
June
30, 2010
|
September
30, 2010
|
||||||||||||||
Stockholders'
Equity
|
||||||||||||||||
As
reported
|
$ | 574,444 | $ | 2,789,522 | $ | 1,308,233 | ||||||||||
Error
|
$ | (577,614 | ) | $ | (834,513 | ) | $ | (654,028 | ) | |||||||
As
restated
|
$ | (3,170 | ) | $ | 1,955,009 | $ | 654,205 |
(d)
|
Exhibits.
|
99.1
|
Press
Release.
|
|
Cytomedix,
Inc.
|
|
|
||
By:
|
/s/ Martin P. Rosendale
|
|
Martin
P. Rosendale
Chief
Executive Officer
|
||
1 Year Cytomedix Chart |
1 Month Cytomedix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions